human
metapneumoviru
hmpv
thought
belong
metapneumoviru
genu
pneumovirina
subfamili
recent
identifi
human
respiratori
pathogen
first
isol
hospit
children
acut
respiratori
infect
ari
netherland
viral
genom
clinic
manifest
epidemiolog
associ
hmpv
similar
human
respiratori
syncyti
viru
hrsv
identifi
import
viral
agent
respons
ari
children
sinc
initi
identif
hmpv
infect
report
worldwid
howev
fluctuat
incid
infect
report
group
differ
area
vari
respiratori
tract
sampl
patient
ari
seroepidemiolog
investig
also
show
preval
hmpv
may
differ
geograph
locat
exampl
netherland
virtual
children
expos
hmpv
age
five
demonstr
hmpv
infect
common
childhood
canada
elisabas
test
use
recombin
nucleocapsid
protein
n
protein
hmpv
produc
baculoviru
reveal
patient
year
age
test
seroposit
hmpv
china
howev
studi
seroepidemeolog
hmpv
limit
unclear
percentag
popul
differ
age
group
infect
viru
n
protein
amino
acid
length
encod
n
gene
hmpv
genom
hmpv
n
protein
abundantli
express
earli
replic
stage
viru
stimul
sustain
immun
respons
amino
acid
ident
hmpv
n
highli
conserv
within
b
subgroup
hmpv
wide
appli
immunoassay
hmpv
infect
investig
seropreval
hmpv
infect
hmpv
n
protein
share
homolog
amino
acid
sequenc
hrsv
previou
studi
shown
obviou
crossreact
immunoassay
elisa
hrsv
n
protein
use
refer
evalu
seropreval
hmpv
assess
seropreval
hmpv
infect
china
use
hmpv
n
protein
antigen
test
serum
sampl
presenc
antihmpv
igg
antibodi
children
adult
free
acut
respiratori
ill
beij
china
igg
antibodi
n
protein
hrsv
test
parallel
control
result
indic
exposur
hmpv
ubiquit
beij
popul
lower
seroposit
rate
geometr
mean
titer
gmt
antihmpv
igg
observ
children
age
six
month
six
year
compar
hrsv
may
reflect
diverg
infect
pattern
hmpv
hrsv
children
data
inform
evalu
social
econom
burden
hmpv
infect
enabl
develop
medic
public
health
strategi
combat
hmpv
infect
popul
recombin
hmpv
hrsv
n
protein
effect
express
e
coli
solubl
protein
recombin
hmpv
n
protein
purifi
cell
lysat
nichel
chromatographi
recombin
hrsv
n
protein
purifi
anion
exchang
chromatographi
follow
nichel
chromatographi
data
shown
puriti
recombin
n
protein
greater
purifi
protein
confirm
western
blot
analysi
use
mous
tag
monoclon
antibodi
primari
antibodi
irdy
goat
antimous
monoclon
antibodi
secondari
antibodi
figur
optim
elisa
condit
perform
chessboard
titrat
test
use
recombin
hmpv
hrsv
n
protein
hmpvposit
neg
sera
sampl
identifi
western
blot
analysi
figur
left
panel
optim
antigen
hmpv
n
protein
concentr
elisa
test
condit
determin
hmpv
serum
dilut
nm
valu
posit
sera
approxim
differ
nm
valu
posit
neg
sera
greatest
figur
right
panel
similarli
determin
optim
assay
condit
hrsv
n
proteinelisa
hrsv
n
protein
serum
dilut
figur
base
elisa
condit
determin
cutoff
valu
assay
twentyeight
antihmpv
igg
neg
antihrsv
igg
neg
sera
sampl
identifi
use
western
blot
analysi
sera
sampl
randomli
collect
children
five
year
age
nm
neg
sampl
determin
elisa
hmpv
n
protein
hrsv
n
protein
mean
valu
nm
hmpv
neg
sera
standard
deviat
sd
mean
valu
hrsv
neg
sera
sd
base
formula
cutoff
valu
mean
nm
neg
sera
three
fold
sd
hmpv
hrsv
posit
cutoff
valu
defin
test
sampl
score
posit
nm
valu
cutoff
valu
sensit
two
elisa
method
determin
use
purifi
murin
igg
hmpv
hrsv
n
protein
limit
detect
igg
igg
respect
test
specif
elisa
method
establish
studi
reaction
mous
sera
influenza
viru
subtyp
human
coronavirus
polyomaviru
jc
hmpv
hrsv
n
protein
evalu
obviou
crossreact
mous
antibodi
hmpv
hrsv
n
protein
data
shown
furthermor
observ
crossreact
hrsv
n
protein
hmpv
n
protein
data
shown
largescal
elisa
screen
test
serum
sampl
evalu
presenc
antihmpv
antihrsv
n
protein
antibodi
analysi
indic
among
sampl
subject
age
mo
subject
age
yr
age
yr
age
yr
age
yr
age
yr
seroposit
hmpv
wherea
subject
age
mo
age
yr
age
yr
age
yr
age
yr
age
yr
seroposit
hrsv
figur
tabl
comparison
hmpv
hrsvposit
sera
statist
analysi
test
demonstr
seroposit
rate
hmpv
significantli
lower
hrsv
age
group
six
month
six
year
wherea
signific
differ
observ
age
group
one
six
month
six
year
year
tabl
character
seropreval
hmpv
infect
sampl
use
studi
analyz
titer
antihmpv
antihrsv
igg
antibodi
sampl
twenti
randomli
select
seroposit
sampl
age
group
analyz
geometr
mean
titer
gmt
antihmpv
igg
antihrsv
igg
significantli
higher
age
group
year
age
group
year
gmt
antihmpv
igg
vs
p
antihrsv
igg
vs
p
mannwhitney
u
test
figur
consist
seroposit
rate
gmt
antihmpv
igg
also
lower
antihrsv
igg
younger
group
six
month
six
year
age
mannwhitney
u
test
p
age
group
proport
specimen
low
antihmpv
igg
titer
significantli
higher
low
antihrsv
igg
titer
vs
test
p
figur
notabl
individu
six
year
age
proport
specimen
high
antihmpv
titer
increas
compar
high
antihrsv
igg
titer
vs
test
p
figur
report
show
high
seropreval
antihmpv
igg
antibodi
beij
area
serum
sampl
includ
studi
randomli
collect
individu
receiv
routin
physic
examin
free
recent
respiratori
infect
thu
data
repres
incid
hmpv
infect
beij
result
indic
virtual
children
age
six
year
expos
hmpv
infect
compar
report
netherland
japan
sampl
test
data
deriv
larger
number
subject
consist
two
report
result
suggest
hmpv
infect
ubiquit
howev
result
show
higher
rate
hmpv
infect
infant
younger
children
report
netherland
japan
found
seropreval
hmpv
children
age
mo
yr
compar
netherland
japan
thu
data
suggest
primari
infect
children
hmpv
may
occur
much
earlier
beij
netherland
japan
discrep
may
caus
differ
exposur
hmpv
differ
geograph
region
factor
social
environment
climat
condit
similarli
hrsv
high
seropreval
rate
beij
data
correl
previou
find
seropreval
increas
age
age
three
children
seroposit
hrsv
interestingli
result
demonstr
seroposit
rate
hmpv
children
six
month
six
year
age
significantli
lower
seroposit
rate
hrsv
p
suggest
hrsv
infect
occur
earlier
hmpv
infect
result
show
seroposit
hmpv
decreas
year
period
matern
antibodi
may
respons
higher
hmpv
seroposit
individu
month
old
seroposit
hmpv
decreas
year
period
level
matern
antibodi
decreas
antibodi
titer
increas
age
repeat
hmpv
infect
notabl
within
age
group
mo
yr
gmt
antihmpv
igg
significantli
lower
antihrsv
igg
significantli
specimen
low
antihmpv
igg
titer
low
antihrsv
igg
titer
reason
dispar
unclear
possibl
infect
hmpv
occur
later
infect
hrsv
thu
lead
delay
increas
seroposit
rate
antibodi
titer
hmpv
like
less
respons
hmpv
exposur
hrsv
would
boost
antibodi
titer
result
higher
antibodi
titer
hrsv
hmpv
howev
largescal
investig
use
sampl
collect
differ
geograph
region
necessari
distinguish
immunolog
respons
two
virus
earli
human
life
find
signific
differ
seropreval
hmpv
hrsv
infect
children
less
six
month
age
reflect
high
level
matern
antibodi
hmpv
hrsv
may
attribut
high
preval
antibodi
adult
tabl
figur
determin
specif
elisa
method
test
reaction
hmpv
hrsv
n
protein
murin
antibodi
multipl
virus
includ
influenza
virus
human
coronavirus
polyomaviru
jc
found
obviou
reactiv
elisa
assay
addit
detect
crossreact
hmpv
n
protein
hrsv
n
protein
result
indic
n
proteinbas
elisa
specif
detect
antihmpv
antihrsv
antibodi
howev
need
evalu
specif
n
proteinbas
elisa
use
antibodi
respiratori
viru
antigen
sensit
elisa
method
detect
hmpv
hrsv
determin
use
purifi
murin
specif
antihmpv
hrsv
n
igg
respect
knowledg
limit
detect
compar
sensit
achiev
method
report
serolog
survey
hmpv
repeat
infect
individu
hmpv
hrsv
report
suggest
immun
hmpv
hrsv
solid
transient
incomplet
heterolog
strain
high
preval
high
titer
hmpv
hrsv
observ
adult
may
suggest
reinfect
hmpv
hrsv
occur
throughout
life
result
suggest
similar
hrsv
infect
hmpv
infect
ubiquit
beij
popul
howev
seropreval
igg
antibodi
hmpv
lower
hrsv
children
six
month
six
year
age
may
reflect
differ
infect
pattern
two
virus
find
provid
inform
aid
develop
strategi
control
prevent
hmpv
infect
viral
rna
nasopharyng
swab
sampl
posit
hmpv
rsvbn
extract
fulllength
n
gene
reversetranscrib
clone
contain
tag
downstream
promot
novagen
wisconsin
usa
recombin
construct
transform
e
coli
novagen
transform
grown
lb
medium
contain
kanamycin
hour
cell
dilut
transfer
fresh
lb
medium
grown
reach
induc
express
recombin
protein
cell
incub
mm
iptg
overnight
hmpv
n
proteinexpress
cell
harvest
centrifug
g
minut
resuspend
lysi
buffer
mm
phosphat
mm
nacl
mm
imidazol
sonic
lysat
centrifug
g
minut
supernat
purifi
use
histrap
hp
ml
column
ge
healthcar
waukesha
usa
cell
express
hrsv
n
protein
harvest
centrifug
g
minut
resuspend
lysi
buffer
mm
phosphat
sonic
lysat
centrifug
g
minut
supernat
purifi
use
histrap
q
ff
ml
column
ge
healthcar
follow
histrap
hp
ml
column
ge
healthcar
purif
n
protein
evalu
sdspage
optic
densiti
scan
use
gene
geniu
bioimag
system
syngen
synopt
ltd
cambridg
uk
yield
purifi
recombin
protein
quantifi
use
protein
assay
kit
thermo
scientif
rockford
usa
serum
specimen
collect
subject
includ
children
beij
children
hospit
adult
beij
blood
center
routin
physic
examin
individu
free
acut
respiratori
infect
least
three
month
prior
sampl
sampl
collect
obtain
inform
consent
either
individu
individu
guardian
sera
separ
immedi
collect
store
inactiv
minut
use
purifi
recombin
protein
separ
sdspage
transfer
onto
nitrocellulos
membran
previous
describ
membran
block
two
hour
nonfat
milk
mous
antihi
monoclon
antibodi
sigma
munich
germani
dilut
nonfat
milk
serum
sampl
dilut
nonfat
milk
ad
membran
incub
one
hour
room
temperatur
membran
wash
three
time
tween
incub
one
hour
room
temperatur
secondari
antibodi
irdy
goat
antimous
monoclon
antibodi
licor
bioscienc
nebraska
usa
horseradish
peroxidaseconjug
goat
antihuman
igg
monoclon
antibodi
sigma
munich
germani
subsequ
membran
wash
three
time
tween
develop
use
odyssey
licor
bioscienc
tetramethylbenzidin
tmb
substrat
thermo
scientif
rockford
usa
accord
manufactur
instruct
chessboard
titrat
test
conduct
use
posit
neg
serum
sampl
randomli
select
western
blot
analysi
use
determin
optim
concentr
coat
antigen
serum
dilut
subsequ
plate
costar
bethesda
usa
coat
purifi
hmpv
n
protein
purifi
hrsv
n
protein
sodium
hydrogen
carbon
buffer
plate
incub
overnight
block
bsa
overnight
wash
three
time
tween
subsequ
dilut
serum
specimen
ad
incub
one
hour
plate
wash
six
time
tween
incub
one
hour
horseradish
peroxidaseconjug
goat
antihuman
igg
sigma
dilut
plate
wash
six
time
solut
antibodi
detect
ad
substrat
solut
b
wantai
biotech
corp
beij
china
follow
incub
minut
reaction
termin
ad
optic
densiti
od
read
nm
nm
averag
od
valu
hmpvneg
human
sera
sampl
n
shown
neg
western
blot
analysi
hmpvn
protein
measur
averag
od
valu
hrsvneg
human
sera
sampl
n
shown
neg
western
blot
analysi
hrsvn
protein
also
measur
cutoff
valu
defin
mean
od
neg
sera
plu
three
standard
deviat
sampl
nm
valu
cutoff
valu
consid
posit
determin
specif
elisa
method
test
mous
sera
inflenza
viru
ha
protein
subtyp
human
coronaviru
n
protein
polyomaviru
jc
protein
reaction
hmpv
hrsv
protein
sampl
sera
test
serial
dilut
twofold
start
dilut
determin
sensit
elisa
method
establish
studi
mice
sera
hmpv
n
protein
hrsv
n
protein
purifi
use
prote
sepharos
column
ge
healthcar
quantifi
use
protein
assay
kit
thermo
scientif
rockford
purifi
murin
igg
hmpv
hrsv
test
serial
dilut
twofold
start
concentr
addit
randomli
select
posit
serum
sampl
group
subject
antihmpv
antihrsv
titer
assay
determin
endpoint
antibodi
titer
titer
calcul
highest
dilut
serum
show
nm
read
two
time
mean
neg
serum
control
start
seroposit
rate
evalu
use
test
mean
antibodi
titer
children
adult
posit
hmpv
hrsv
exposur
analyz
use
mannwhitney
u
test
p
valu
consid
statist
signific
author
declar
compet
interest
gl
rg
jw
design
studi
gl
lg
cw
conduct
experi
jw
charg
collect
sera
specimen
gl
rg
gp
gv
jw
wrote
manuscript
gv
gp
jw
th
revis
manuscript
author
read
approv
final
manuscript
